800,000 Shares in DexCom, Inc. $DXCM Acquired by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 800,000 shares of the medical device company’s stock, valued at approximately $50,240,000. DexCom comprises about 1.4% of Mizuho Markets Americas LLC’s portfolio, making the stock its 24th biggest holding.

Several other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of DexCom in the 4th quarter valued at $483,356,000. AQR Capital Management LLC raised its holdings in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after buying an additional 2,658,158 shares in the last quarter. Employees Provident Fund Board acquired a new position in shares of DexCom during the 4th quarter worth $145,352,000. J. Stern & Co. LLP lifted its position in shares of DexCom by 2,114.8% during the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after buying an additional 1,529,641 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of DexCom by 271.4% during the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after buying an additional 1,509,219 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent analyst reports. Citigroup reiterated a “buy” rating and issued a $84.00 target price (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Truist Financial lifted their price target on shares of DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a report on Thursday, July 16th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.36.

Insider Buying and Selling

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,750 shares of company stock valued at $5,163,241 over the last three months. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $70.48 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The business has a 50-day simple moving average of $72.26 and a two-hundred day simple moving average of $68.92. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market cap of $27.20 billion, a PE ratio of 30.12, a PEG ratio of 1.18 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company earned $0.32 earnings per share. The business’s quarterly revenue was up 15.0% on a year-over-year basis. Analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.